Literature DB >> 16246551

N-(4-{[4-(1H-Benzoimidazol-2-yl)-arylamino]-methyl}-phenyl)-benzamide derivatives as small molecule heparanase inhibitors.

Yong-Jiang Xu1, Hua-Quan Miao, Weitao Pan, Elizabeth C Navarro, James R Tonra, Stan Mitelman, M Margarita Camara, Dhanvanthri S Deevi, Alexander S Kiselyov, Paul Kussie, Wai C Wong, Hu Liu.   

Abstract

A novel class of N-(4-{[4-(1H-benzoimidazol-2-yl)-arylamino]-methyl}-phenyl)-benzamides are described as inhibitors of the endo-beta-glucuronidase heparanase. Among them are N-(4-{[4-(1H-benzoimidazol-2-yl)-phenylamino]-methyl}-phenyl)-3-bromo-4-methoxy-benzamide (15h), and N-(4-{[5-(1H-benzoimidazol-2-yl)-pyridin-2-ylamino]-methyl}- phenyl)-3-bromo-4-methoxy-benzamide (23) which displayed good heparanase inhibitory activity (IC(50) 0.23-0.29 microM), with the latter showing oral exposure in mice.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16246551     DOI: 10.1016/j.bmcl.2005.09.070

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  13 in total

1.  Novel 1, 3-N, O-Spiroheterocyclic compounds inhibit heparanase activity and enhance nedaplatin-induced cytotoxicity in cervical cancer cells.

Authors:  Yanan Song; Bin Hu; Hongjie Qu; Lu Wang; Yunxiao Zhang; Jinchao Tao; Jinquan Cui
Journal:  Oncotarget       Date:  2016-06-14

2.  Primary anti-proliferative activity evaluation of 1-(quinolizidin-1'-yl)methyl- and 1-(ω-tert-amino)alkyl-substituted 2-phenyl-, 2-benzyl- and 2-[(benzotriazol-1/2-yl)methyl]benzimidazoles on human cancer cell lines.

Authors:  Michele Tonelli; Bruno Tasso; Lorenzo Mina; Giuseppe Paglietti; Vito Boido; Fabio Sparatore
Journal:  Mol Divers       Date:  2013-04-13       Impact factor: 2.943

Review 3.  Heparanase: a target for drug discovery in cancer and inflammation.

Authors:  E A McKenzie
Journal:  Br J Pharmacol       Date:  2007-03-05       Impact factor: 8.739

4.  Mechanisms of heparanase inhibition by the heparan sulfate mimetic PG545 and three structural analogues.

Authors:  Edward Hammond; Paul Handley; Keith Dredge; Ian Bytheway
Journal:  FEBS Open Bio       Date:  2013-08-02       Impact factor: 2.693

5.  Identification of Novel Class of Triazolo-Thiadiazoles as Potent Inhibitors of Human Heparanase and their Anticancer Activity.

Authors:  C P Baburajeev; Chakrabhavi Dhananjaya Mohan; Shobith Rangappa; Daniel J Mason; Julian E Fuchs; Andreas Bender; Uri Barash; Israel Vlodavsky; Kanchugarakoppal S Rangappa
Journal:  BMC Cancer       Date:  2017-03-31       Impact factor: 4.430

Review 6.  Heparin Binding Proteins as Therapeutic Target: An Historical Account and Current Trends.

Authors:  Giancarlo Ghiselli
Journal:  Medicines (Basel)       Date:  2019-07-29

7.  Computational Investigation Identified Potential Chemical Scaffolds for Heparanase as Anticancer Therapeutics.

Authors:  Shraddha Parate; Vikas Kumar; Jong Chan Hong; Keun Woo Lee
Journal:  Int J Mol Sci       Date:  2021-05-18       Impact factor: 5.923

Review 8.  The Role of Heparanase and Sulfatases in the Modification of Heparan Sulfate Proteoglycans within the Tumor Microenvironment and Opportunities for Novel Cancer Therapeutics.

Authors:  Edward Hammond; Ashwani Khurana; Viji Shridhar; Keith Dredge
Journal:  Front Oncol       Date:  2014-07-24       Impact factor: 6.244

9.  Structural characterization of human heparanase reveals insights into substrate recognition.

Authors:  Liang Wu; Cristina M Viola; Andrzej M Brzozowski; Gideon J Davies
Journal:  Nat Struct Mol Biol       Date:  2015-11-16       Impact factor: 15.369

Review 10.  The Development of Assays for Heparanase Enzymatic Activity: Towards a Gold Standard.

Authors:  Mohit Chhabra; Vito Ferro
Journal:  Molecules       Date:  2018-11-14       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.